0.9564
10-January-25 15:45:00
15 minutes delayed
Stocks
-0.0286
-2.90%
Today's range
0.9260 - 0.9809
ISIN
N/A
Source
NASDAQ
Kronos Bio Announces Positive End-of-Phase 2 Meeting with FDA for Entospletinib in Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia (AML)
04 Mar 2021 06:00:01 By Nasdaq GlobeNewswire
Kronos Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers
25 Feb 2021 07:00:01 By Nasdaq GlobeNewswire
Kronos Bio Appoints Marianne De Backer, Ph.D., to Board of Directors
26 Jan 2021 07:00:02 By Nasdaq GlobeNewswire